You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antibody Drug Conjugate

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Advanced or Metastatic Solid Tumors Trial in Toulouse, Villejuif, Barcelona (W0101 - Cohort A1, W0101 - Cohort A2, W0101 -

Active, not recruiting
  • Advanced or Metastatic Solid Tumors
  • W0101 - Cohort A1
  • +2 more
  • Toulouse, France
  • +2 more
Dec 19, 2022

Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco (FOR46, Enzalutamide, Pegfilgrastim)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Prostate Cancer
  • FOR46
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jun 1, 2022

Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting

Recruiting
  • Breast Neoplasms
  • Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jul 30, 2022

Metastatic Colorectal Cancer Trial (IMMU 130)

Withdrawn
  • Metastatic Colorectal Cancer
  • IMMU 130
  • (no location specified)
Aug 12, 2021

Breast Cancer Trial in Spain (U3 1402)

Recruiting
  • Breast Cancer
  • U3 1402
  • Badalona, Barcelona, Spain
  • +9 more
Apr 1, 2022

Solid Tumor Trial in Belgium, Netherlands, United Kingdom (SYD985 + Niraparib)

Active, not recruiting
  • Solid Tumor
  • SYD985 + Niraparib
  • Antwerp, Belgium
  • +5 more
Jan 23, 2023

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,

Not yet recruiting
  • Metastatic Penile Squamous Cell Carcinoma
  • +3 more
  • Enfortumab Vedotin
  • Phoenix, Arizona
  • +2 more
Oct 23, 2023

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 Trial in Seattle

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • +2 more
  • Lymphadenectomy
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 9, 2023

Relapsed/Refractory Multiple Myeloma Trial in Worldwide (Dose Escalation, MEDI2228, ADC (antibody drug conjugate), Dose

Completed
  • Relapsed/Refractory Multiple Myeloma
  • Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
  • Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
  • Phoenix, Arizona
  • +10 more
Mar 25, 2022

Multiple Myeloma Trial in United States (hLL1-DOX (the doxorubicin conjugate of milatuzumab))

Terminated
  • Multiple Myeloma
  • hLL1-DOX (the doxorubicin conjugate of milatuzumab)
  • Orlando, Florida
  • +4 more
Aug 12, 2021

Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter Trial in

Recruiting
  • Urothelial Cancer
  • +3 more
  • Sacituzumab Govitecan (SG)
  • Enfortumab vedotin-ejfv (EV)
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 28, 2022

Advanced Solid Tumor, Advanced Cancer, Triple Negative Breast Cancer Trial in Nashville, Houston, San Antonio (NBE-002)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • Nashville, Tennessee
  • +2 more
Mar 3, 2022

Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma Trial (AMT-151)

Not yet recruiting
  • Advanced Solid Tumor
  • +18 more
  • (no location specified)
Aug 10, 2022

Endometrial Carcinoma Trial in New Haven (Sacituzumab Govitecan)

Recruiting
  • Endometrial Carcinoma
  • Sacituzumab Govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Apr 4, 2022

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Nivolumab
  • Duarte, California
    City of Hope Medical Center
Feb 16, 2022

Solid Tumor Trial in United States (TR1801-ADC)

Active, not recruiting
  • Unspecified Adult Solid Tumor, Protocol Specific
  • TR1801-ADC
  • Los Angeles, California
  • +4 more
Oct 30, 2022

Colorectal Cancer Trial in Japan, Spain, United States (M9140)

Recruiting
  • Colorectal Cancer
  • Houston, Texas
  • +4 more
Jul 15, 2022

Breast Tumors Trial in France (DS-8201a)

Active, not recruiting
  • Breast Tumors
  • Angers, France
  • +20 more
Feb 1, 2022

Multiple Myeloma Trial in Aichi, Okayama, Tokyo (Belantamab mafodotin, Bortezomib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Aichi, Japan
  • +3 more
Feb 8, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Birmingham, Alabama
  • +25 more
Dec 9, 2022

Advanced/ Metastatic Solid Tumors Trial in Shanghai (FDA018-ADC)

Recruiting
  • Advanced/ Metastatic Solid Tumors
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 14, 2021